Article Details

Landos Biopharma Announces First Patient Dosed in a Phase 2 Study of Omilancor for Moderate ...

Retrieved on: 2021-05-06 20:03:45

Tags for this article:

Click the tags to see associated articles and topics

Landos Biopharma Announces First Patient Dosed in a Phase 2 Study of Omilancor for Moderate .... View article details on hiswai:

Excerpt

BLACKSBURG, Va., May 06, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma (NASDAQ: LABP), a clinical-stage biopharmaceutical company ...

Article found on: www.globenewswire.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up